1 completed, 1 unknown. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Mucpharm Pty Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nebulised BromAc in Healthy Volunteers BromAc - COVID-19 Pneumonia, Bromelains Adverse Reaction | Phase 1 | Completed | Mucpharm Pty Ltd | 12 | 2022-07-27 | 2022-09-15 |
| Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease Bromelains, Acetylcysteine - COVID-19 Pneumonia, COVID-19 | Phase 1 / Phase 2 | Unknown | Mucpharm Pty Ltd | 30 | 2022-05-01 | 2022-02-28 |
Pneumonia, Ventilator-Associated (2) · COVID-19 (1) · Medullary cystic kidney disease 1 (1)
Acetylcysteine (1) · Bromelains (1) · bromelain and acetylcysteine drug combination (1)
Australia (1)
Frank MP van Haren, MD, PhD (1) · Frank van Haren, MD, PhD (1)